Post Content

Before drug manufacturers ship vaccines to distributors they, along with the Food and Drug Administration (FDA), always test them to determine that they meet all safety and efficacy standards. As part of its quality assurance program, manufacturer Sanofi Pasteur, performs additional routine, ongoing tests of their flu vaccines to ensure that they continue to meet required specifications after they have been distributed health care providers.

This week, after performing these tests, Sanofi Pasteur notified Centers for Disease Control (CDC) and the FDA that the antigen content in a batch (known as a "lot") of syringes intended for children 6 months through 35 months of age distributed to providers in November, had dropped below a pre-specified limit making them slightly less potent.

Consequently, Sanofi Pasteur tested additional lots and found that three others also had an antigen content that had fallen below pre-specified limits. This means that doses from these four vaccine lots no longer meet the specifications for antigen content. Therefore, Sanofi is conducting a voluntary recall of these affected lots and has asked providers to return any vaccine they may have from these lots to the manufacturer.

The affected vaccine met all specifications at the time of release and both CDC and FDA have determined that there are no safety concerns for children who received this vaccine. Parents of children who received vaccines from the recalled lots do not need to take any action other than make sure their child receives their second dose if they have not already. There is NO need to revaccinate children who have received vaccine from these lots. The antigen content in the affected lots of vaccine is only slightly below the specification limit and experts expect it to still be effective against the H1N1 flu.

This drop in antigen content below the required specification only occurred in Sanofi Pasteur’s pediatric H1N1 monovalent vaccine in 0.25 mL pre-filled syringes. The same vaccine packaged in other forms, such as pre-filled syringes for older children and adults and multi-dose vials, continue to meet specifications.

For additional information please see CDC’s Questions and Answers related to the withdrawn vaccine at http://www.cdc.gov/h1n1flu/vaccination/syringes_qa.htm

We encourage all residents to utilize the comments section on this blog to engage with us and each other. While we cannot respond to every comment or question directly, we find them very helpful to understand your questions and concerns and plan for future posts.

Written By:


Communications Office

Recent Posts

Weekly Flu Report, February 24, 2017 posted on Feb 24

The latest weekly flu report shows that rates of flu-like illness declined slightly over the past seven days. It’s too soon to tell if we’ve seen the peak of flu activity this season, and in any case. we can expect to see flu continuing to circulate in   …Continue Reading Weekly Flu Report, February 24, 2017

Weekly Flu Report, February 17, 2017 posted on Feb 17

Rates of flu-like illness have risen over the past seven days, according to the latest weekly flu report. If you haven’t gotten your flu shot yet, it’s not too late – there’s still plenty of flu vaccine available. Call your health care provider or local board   …Continue Reading Weekly Flu Report, February 17, 2017

Love Your Heart This Valentine’s Day! posted on Feb 14

Love Your Heart This Valentine’s Day!

By Eliza Mellion, M.S. This Valentine’s Day, don’t forget that—thanks to the American Heart Association—February is American Heart Month! It can be hard to resist the chocolates, candy hearts, and pink-frosted cupcakes that this holiday brings.  While it’s fun to shower our loved ones with   …Continue Reading Love Your Heart This Valentine’s Day!